ArticleInternational journal of molecular sciences2025
A Study on the Levels of Selected Proangiogenic Proteins in Human Tissues and Plasma in Relation to Brain Glioma.
Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The atypical kinase right open reading frame kinase 1 suppresses glioma cell growth through mammalian target of rapamycin inhibition and apoptotic signaling activation.Translational cancer research · 2026Article
- Current Pharmacotherapeutic Strategies in Diffuse Gliomas: Focus on Glioblastoma, IDH-Wildtype, and Emerging Targeted Therapies for IDH-Mutant Tumors.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Correlation Between Intrafollicular IL-10, Progesterone, and Bovine Oocyte Developmental Competence.International journal of molecular sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Brain glioma is one of the most common malignant tumors of brain tissue. It is characterized by rich vascularization, which indicates the significant participation of angiogenesis in its growth and development. In its first stages, the disease is very often asymptomatic, and late diagnosis significantly limits possibilities of treatment. Tumor angiogenesis, i.e., the formation of new vessels, requires the presence of angiogenic compounds that will enable tumor progression by creating a path for the supply of nutrients. The proangiogenic compounds involved in the development of glioma include hypoxia-inducible factor 1α (HIF-1α), angiopoietin-2 (ANG-2), and interleukin-1β (IL-1β). The aim of this study was to analyze changes in the levels of these proteins in plasma samples of patients diagnosed with brain glioma in stages G1 to G4, and in a control group, using SPRi biosensors. The results obtained in plasma were compared with the concentrations obtained during the analysis of tissue homogenates from patients with glioma in stages G2 to G4. A statistically significant difference in plasma concentrations was obtained between the patient group and the control group. The concentrations of the markers in tissue homogenate samples were statistically higher than in blood plasma. There was no significant effect of gender, diet, smoking, or the patient's general health condition (Karnofsky score) on the course of the disease. These factors do not directly increase the risk of developing brain glioma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.